The Weekly Pulse — Edition 11: December 7, 2025
Published · Researched 2026-09-22
The week in one paragraph. On May 16, 2026, firefighters at Fort Worth's Fire Station 8 found Jake the pit bull chained to their flagpole, a water bottle at his feet holding a three-page handwritten letter. The letter was from Tom, 65, a disabled veteran who had spent 20 months in a homeless camp after his lease wasn't renewed. He wrote that Jake was all he had and begged them to help his baby. The firefighters took Jake in as the station dog and posted his arrival on Facebook; the department's HOPE Team tracked Tom down, arranged medical checkups, and asked what he needed most — his answer was a way to stay near Jake. Community group Operation Texas Strong coordinated, Bennett's Camping Center in Granbury donated a 2012 RV for Tom's home, and a GoFundMe covered expenses. A surrender became a double rescue: the dog got a station full of firefighters, the man got a home and care. Still watching: Tom's last name wasn't reported, and the RV donation date sits in the weeks after May 16 without an exact day.
Rising
- Medical science, prevention and durability. U.S. surveillance of the 2024–2025 RSV season showed infant hospitalization rates 28% and 43% lower across two national networks after the rollout of nirsevimab — a single injection protecting a baby through their first RSV season — with effectiveness studies estimating roughly 81% protection against hospitalization. That's real-world data, not trial projections, on one of the leading causes of infant hospital stays. Still watching: direct parent or community posts about nirsevimab weren't observed; the layer here is public-health press.
- The cell-therapy frontier holds. The FDA approved Amtagvi in February 2024 as the first tumor-derived T-cell therapy for any solid tumor — for adults with advanced melanoma who had failed standard treatment, including PD-1 blockade. The five-year analysis showed responses measured in years: median response duration beyond three years, nearly a third of responders still responding at five years, 20% five-year overall survival, with 2026 real-world data at a 44% response rate. The label carries a serious boxed warning — treatment-related mortality, prolonged cytopenia, severe infection, organ impairment — stated, not softened. Still watching: direct social posts about Amtagvi weren't observed.
- Animals thriving, double feature. Fota Wildlife Park in Cork, Ireland, announced two endangered-species litters in one summer: two Sumatran tiger cubs born June 16, 2026 to first-time mother Jambi — the park's first-ever multiple-cub tiger litter — and three Asian lion cubs born July 1 to mother Arya. All five were feeding well and thriving with their mothers under a hands-off approach. The park's lead ranger said he had to pinch himself announcing both in one summer. Still watching: the cubs' names and public-viewing dates weren't announced.
- Community, hometown edition. The Paynther family in Canton, Ohio, received keys to their Habitat for Humanity home — with Pro Football Hall of Fame staff helping on the build. A hometown institution literally building its neighbors' future. Still watching: the dedication date wasn't captured, and the specific Facebook reel URL wasn't preserved.
Falling
- The idea that one shot can't move a population-level needle — two surveillance networks both showed double-digit drops in RSV hospitalizations.
- "Cell therapy only works for blood cancers" — the first solid-tumor approval now holds five years of durability data.
- Surrender-as-ending — Jake's surrender became a veteran's rescue too.
Quiet signals
- Fota's cubs — two litters announced, names and debut dates still to come. Watch how the park handles the attention; the thriving-with-mothers reporting so far is the number that matters.
- Amtagvi at five years — durable responses in treatment-refractory patients, but the boxed warning gives this one real edges. Patient-community reception wasn't observed; that's the missing signal.
Scoreboard. N/A — editions are being written out of sequence; no prior calls to grade.
One line to close. A veteran, a pit bull, a baby-saving shot, and a therapy that refused to quit — December's first week earned its name.